Genetic heterogeneity is an additional phenomenon that can frequently result in discrepant or equivocal FISH, DISH, and IHC results across different tumor sections and metastatic lesions, affecting the accurate assessment of HER2 status and the determination of appropriate therapy17. This evidence concerns the gene ERBB2 and neoplasm.